Time-dependent pharmacokinetics of 5-fluorouracil and association with treatment tolerability in the adjuvant setting of colorectal cancer

Journal of Clinical Pharmacology

Volumn 52, Issue 3, 2012, Pages 361-369

  Ibrahim, Toni ^a   Di Paolo, Antonello ^b   Amatori, Federica ^b   Mercatali, Laura ^a   Ravaioli, Elena ^a   Flamini, Emanuela ^a   Sacanna, Emanuele ^a   Del Tacca, Mario ^b   Danesi, Romano ^b   Amadori, Dino ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

5 Fluorouracil; metabolism; pharmacokinetics; toxicity

Indexed keywords

DIHYDROFLUOROURACIL; FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMORADIOTHERAPY; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER STAGING; COLORECTAL CANCER; DIARRHEA; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; FEMALE; GRANULOCYTOPENIA; HAND FOOT SYNDROME; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; PARESTHESIA; SEX DIFFERENCE; TRANSIENT ISCHEMIC ATTACK; TREATMENT OUTCOME; VOMITING;

AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED;

EID: 84860174896     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270010396710     Document Type: Article

References (27)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005 ; 55: 74-108
2. Hind D, Tappenden P, Tumur I, et al. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation. Health Technol Assess. 2008 ; 12: iii xi - ix 162
3. Nakata B, Sowa M, Tsuji A, et al. Continuous infusion of 5-fluorouracil with versus without low-dose, consecutive administration of cisplatin in advanced colorectal cancer: a prospective randomized phase II study. J Exp Clin Cancer Res. 2007 ; 26: 51-60
4. Di Paolo A, Ibrahim T, Danesi R, et al. Relationship between plasma concentrations of 5-fluorouracil and 5-fluoro-5,6-dihydrouracil and toxicity of 5-fluorouracil infusions in cancer patients. Ther Drug Monit. 2002 ; 24: 588-593
5. Bin Q, Li J, Liao C, Cao Y, Gao F. Oral uracil-tegafur plus leucovorin versus fluorouracil bolus plus leucovorin for advanced colorectal cancer: a meta-analysis of five randomized controlled trials [published online ahead of print December 28, 2009]. Colorectal Dis. :
6. Tam VC, Rask S, Koru-Sengul T, Dhesy-Thind S. Generalizability of toxicity data from oncology clinical trials to clinical practice: toxicity of irinotecan-based regimens in patients with metastatic colorectal cancer. Curr Oncol. 2009 ; 16: 13-20
7. Bocci G, Barbara C, Vannozzi F, et al. A pharmacokinetic-based test to prevent severe 5-fluorouracil toxicity. Clin Pharmacol Ther. 2006 ; 80: 384-395
8. Ciccolini J, Mercier C, Evrard A, et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther Drug Monit. 2006 ; 28: 678-685
9. Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluorouracil-related severe toxicity: a comparison of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase deficiency. Cancer Lett. 2007 ; 249: 271-282
10. Nishiyama M, Yamamoto W, Park JS, et al. Low-dose cisplatin and 5-fluorouracil in combination can repress increased gene expression of cellular resistance determinants to themselves. Clin Cancer Res. 1999 ; 5: 2620-2628
11. Schneider S, Uchida K, Brabender J, et al. Downregulation of TS, DPD, ERCC1, GST-Pi, EGFR, and HER2 gene expression after neoadjuvant three-modality treatment in patients with esophageal cancer. J Am Coll Surg. 2005 ; 200: 336-344
12. Aschele C, Sobrero A, Faderan MA, Bertino JR. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. Cancer Res. 1992 ; 52: 1855-1864
13. Aschele C, Debernardis D, Bandelloni R, et al. Thymidylate synthase protein expression in colorectal cancer metastases predicts for clinical outcome to leucovorin-modulated bolus or infusional 5-fluorouracil but not methotrexate-modulated bolus 5-fluorouracil. Ann Oncol. 2002 ; 13: 1882-1892
14. Di Paolo A, Vannozzi F, Danesi R, et al. Effect of 5-fluorouracil on dihydropyrimidine dehydrogenase activity in colorectal cancer patients. Proceedings from the 93rd annual meeting of the American Association for Cancer Research ; San Francisco, CA ;..
15. Di Paolo A, Danesi R, Vannozzi F, et al. Limited sampling model for the analysis of 5-fluorouracil pharmacokinetics in adjuvant chemotherapy for colorectal cancer. Clin Pharmacol Ther. 2002 ; 72: 627-637
16. Di Paolo A, Danesi R, Ciofi L, et al. Improved analysis of 5-fluorouracil and 5,6-dihydro-5-fluorouracil by HPLC with diode array detection for determination of cellular dihydropyrimidine dehydrogenase activity and pharmacokinetic profiling. Ther Drug Monit. 2005 ; 27: 362-368
17. Gibiansky E, Zhang J, Williams D, Wang Z, Ouellet D. Population pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura [published online ahead of print July 27, 2010]. J Clin Pharmacol. :
18. Tarning J, McGready R, Lindergardh N, et al. Population pharmacokinetics of lumefantrine in pregnant women treated with artemether-lumefantrine for uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother. 2009 ; 53: 3837-3846
19. Gamelin E, Delva R, Jacob J, et al. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer. J Clin Oncol. 2008 ; 26: 2099-2105
20. Saif MW, Choma A, Salamone SJ, Chu E. Pharmacokinetically guided dose adjustment of 5-fluorouracil: a rational approach to improving therapeutic outcomes. J Natl Cancer Inst. 2009 ; 101: 1543-1552
21. McLeod HL, Sludden J, Hardy SC, Lock RE, Hawksworth GM, Cassidy J. Autoregulation of 5-fluorouracil metabolism. Eur J Cancer. 1998 ; 34: 1623-1627
22. Kashima N, Ueda M, Kanazawa J. Effect of 5-fluorouracil and epidermal growth factor on cell growth and dihydropyrimidine dehydrogenase regulation in human uterine cervical carcinoma SKG-IIIb cells. Cancer Sci. 2003 ; 94: 821-825
23. Matsusaka S, Nagareda T, Yamasaki H. Does cisplatin (CDDP) function as a modulator of 5-fluorouracil (5-FU) antitumor action? A study based on a clinical trial. Cancer Chemother Pharmacol. 2005 ; 55: 387-392
24. Hoshino S, Yamashita Y, Maekawa T, Shirakusa T. Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients. Cancer Chemother Pharmacol. 2005 ; 56: 648-652
25. Ploylearmsaeng SA, Fuhr U, Jetter A. How may anticancer chemotherapy with fluorouracil be individualised?. Clin Pharmacokinet. 2006 ; 45: 567-592
26. Bocci G, Di Paolo A, Barbara C, et al. Pharmacokinetics, a main actor in a many-sided approach to severe 5-FU toxicity prediction. Br J Clin Pharmacol. 2009 ; 67: 132-134
27. Del Re M, Di Paolo A, van Schaik RH, et al. Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?. EPMA J. 2010 ; 1: 495-502